Clinical Trials
18
Active:12
Completed:6
Trial Phases
3 Phases
Phase 1:13
Phase 2:1
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 1
13 (72.2%)Phase 3
4 (22.2%)Phase 2
1 (5.6%)A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 2517
- Registration Number
- NCT05505734
- Locations
- 🇺🇸
Pulmonary Associates of Mobile PC, Mobile, Alabama, United States
🇺🇸One of a Kind Clinical Research Center, Paradise Valley, Arizona, United States
🇺🇸Fiel Family and Sports Medicine/CCT Research, Tempe, Arizona, United States
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: BDA MDI (PT027) 160/180 μg
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 12
- Registration Number
- NCT04848662
- Locations
- 🇺🇸
IPS Research, Oklahoma City, Oklahoma, United States
🇺🇸TTS Research, Boerne, Texas, United States
A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma
Phase 3
Completed
- Conditions
- Exercise Induced Bronchospasm
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 60
- Registration Number
- NCT04234464
- Locations
- 🇺🇸
Research Site, Burke, Virginia, United States
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)Combination Product: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)Other: Placebo metered-dose inhaler / Placebo MDI
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 1001
- Registration Number
- NCT03847896
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μgCombination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 3132
- Registration Number
- NCT03769090
- Locations
- 🇬🇧
Research Site, Wokingham, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found